Karolinska Development AB (publ) (KDEV.ST)
SEK 1.0
(0.1%)
SEK 1.0
(0.1%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.51 Million SEK | -88.5% |
| 2022 | 34.07 Million SEK | 10.69% |
| 2021 | 30.78 Million SEK | -6.08% |
| 2020 | 32.77 Million SEK | -22.63% |
| 2019 | 42.36 Million SEK | 46.03% |
| 2018 | 29.01 Million SEK | -20.54% |
| 2017 | 36.5 Million SEK | 11.09% |
| 2016 | 32.86 Million SEK | -29.69% |
| 2015 | 46.74 Million SEK | -31.86% |
| 2014 | 68.59 Million SEK | -40.43% |
| 2013 | 115.14 Million SEK | -34.93% |
| 2012 | 176.96 Million SEK | -56.96% |
| 2011 | 411.15 Million SEK | 14.48% |
| 2010 | 359.15 Million SEK | 720.35% |
| 2009 | 43.78 Million SEK | 334.9% |
| 2008 | 10.06 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.46 Million SEK | -44.47% |
| 2024 Q2 | 8.92 Million SEK | 630.26% |
| 2023 FY | 3.92 Million SEK | -88.5% |
| 2023 Q4 | 4.43 Million SEK | -6.51% |
| 2023 Q3 | 4.74 Million SEK | -46.24% |
| 2023 Q1 | 7.9 Million SEK | -3.02% |
| 2023 Q2 | 8.83 Million SEK | 11.77% |
| 2022 Q4 | 8.14 Million SEK | 39.19% |
| 2022 Q2 | 8.5 Million SEK | -26.51% |
| 2022 Q1 | 11.56 Million SEK | 41.95% |
| 2022 FY | 34.07 Million SEK | 10.69% |
| 2022 Q3 | 5.85 Million SEK | -31.15% |
| 2021 Q3 | 7.79 Million SEK | 5.99% |
| 2021 Q2 | 7.35 Million SEK | -1.57% |
| 2021 Q4 | 8.15 Million SEK | 4.5% |
| 2021 FY | 30.78 Million SEK | -6.08% |
| 2021 Q1 | 7.47 Million SEK | 15.59% |
| 2020 Q1 | 7.78 Million SEK | -48.69% |
| 2020 FY | 32.77 Million SEK | -22.63% |
| 2020 Q3 | 9.07 Million SEK | -3.88% |
| 2020 Q4 | 6.46 Million SEK | -28.75% |
| 2020 Q2 | 9.44 Million SEK | 21.24% |
| 2019 Q2 | 10.77 Million SEK | 17.98% |
| 2019 Q4 | 15.17 Million SEK | 108.65% |
| 2019 FY | 42.36 Million SEK | 46.03% |
| 2019 Q3 | 7.27 Million SEK | -32.49% |
| 2019 Q1 | 9.13 Million SEK | 45.93% |
| 2018 Q3 | 6.89 Million SEK | 8.68% |
| 2018 Q1 | 9.52 Million SEK | -12.79% |
| 2018 FY | 29.01 Million SEK | -20.54% |
| 2018 Q4 | 6.25 Million SEK | -9.16% |
| 2018 Q2 | 6.34 Million SEK | -33.41% |
| 2017 Q1 | 8.17 Million SEK | -17.88% |
| 2017 Q4 | 10.91 Million SEK | 22.13% |
| 2017 Q2 | 8.47 Million SEK | 3.66% |
| 2017 FY | 36.5 Million SEK | 11.09% |
| 2017 Q3 | 8.93 Million SEK | 5.46% |
| 2016 Q1 | 8.42 Million SEK | -31.06% |
| 2016 FY | 32.86 Million SEK | -29.69% |
| 2016 Q3 | 7.82 Million SEK | 17.43% |
| 2016 Q4 | 9.95 Million SEK | 27.29% |
| 2016 Q2 | 6.66 Million SEK | -20.94% |
| 2015 Q3 | 8.08 Million SEK | -33.84% |
| 2015 FY | 46.74 Million SEK | -31.86% |
| 2015 Q1 | 14.21 Million SEK | -37.13% |
| 2015 Q2 | 12.22 Million SEK | -13.98% |
| 2015 Q4 | 12.22 Million SEK | 51.12% |
| 2014 Q2 | 13.87 Million SEK | -1.83% |
| 2014 FY | 68.59 Million SEK | -40.43% |
| 2014 Q4 | 22.6 Million SEK | 25.67% |
| 2014 Q3 | 17.98 Million SEK | 29.66% |
| 2014 Q1 | 14.13 Million SEK | -40.78% |
| 2013 Q4 | 23.86 Million SEK | 5.22% |
| 2013 Q3 | 22.67 Million SEK | -16.32% |
| 2013 Q2 | 27.1 Million SEK | -34.7% |
| 2013 FY | 115.14 Million SEK | -34.93% |
| 2013 Q1 | 41.5 Million SEK | -24.28% |
| 2012 Q2 | 49.56 Million SEK | -49.24% |
| 2012 Q1 | 97.65 Million SEK | -66.83% |
| 2012 Q4 | 54.8 Million SEK | 46.1% |
| 2012 Q3 | 37.51 Million SEK | -24.32% |
| 2012 FY | 176.96 Million SEK | -56.96% |
| 2011 Q1 | 44.52 Million SEK | 0.0% |
| 2011 Q4 | 294.42 Million SEK | 635.81% |
| 2011 FY | 411.15 Million SEK | 14.48% |
| 2011 Q2 | 41.75 Million SEK | -6.21% |
| 2011 Q3 | 40.01 Million SEK | -4.17% |
| 2010 FY | 359.15 Million SEK | 720.35% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | 43.78 Million SEK | 334.9% |
| 2008 FY | 10.06 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| NextCell Pharma AB | -576.01 Thousand SEK | 1058.128% |
| Biovica International AB (publ) | 133.72 Million SEK | 95.873% |
| Abliva AB (publ) | 27.86 Million SEK | 80.195% |
| Active Biotech AB (publ) | 44.8 Million SEK | 87.683% |
| Aptahem AB (publ) | 10.01 Million SEK | 44.881% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 98.203% |
| BioInvent International AB (publ) | 441.4 Million SEK | 98.75% |
| BioArctic AB (publ) | 89.62 Million SEK | 93.842% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 93.364% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.636% |
| Cantargia AB (publ) | 290.01 Million SEK | 98.097% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 74.793% |
| CombiGene AB (publ) | 44.14 Million SEK | 87.498% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 97.148% |
| Fluicell AB (publ) | 28.61 Million SEK | 80.714% |
| Genovis AB (publ.) | 88.19 Million SEK | 93.742% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 99.358% |
| Mendus AB (publ) | 129.13 Million SEK | 95.726% |
| LIDDS AB (publ) | 27.75 Million SEK | 80.113% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 68.789% |
| Saniona AB (publ) | 1.07 Million SEK | -412.442% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 72.112% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 87.054% |
| Xintela AB (publ) | 57.31 Million SEK | 90.371% |
| Amniotics AB (publ) | 29.07 Million SEK | 81.016% |
| Corline Biomedical AB | 30.16 Million SEK | 81.706% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 80.516% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 95.903% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 90.49% |
| Intervacc AB (publ) | 79.78 Million SEK | 93.083% |
| Kancera AB (publ) | 63.07 Million SEK | 91.25% |
| Lipum AB (publ) | 37.3 Million SEK | 85.207% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | 23.918% |
| Nanologica AB (publ) | 69.88 Million SEK | 92.103% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 98.283% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 98.457% |
| AcouSort AB (publ) | 25.87 Million SEK | 78.671% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 96.14% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 94.954% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 95.939% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 66.35% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 96.963% |
| Simris Alg AB (publ) | 38.64 Million SEK | 85.718% |
| Ziccum AB (publ) | 27.87 Million SEK | 80.203% |
| SynAct Pharma AB | 224.49 Million SEK | 97.542% |
| OncoZenge AB (publ) | 15.9 Million SEK | 65.3% |
| Camurus AB (publ) | 1.05 Billion SEK | 99.479% |
| 2cureX AB (publ) | 36.51 Million SEK | 84.887% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 62.335% |
| Isofol Medical AB (publ) | 7.26 Million SEK | 24.064% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 76.96% |
| I-Tech AB | 40.14 Million SEK | 86.253% |
| Cyxone AB (publ) | 28.21 Million SEK | 80.439% |
| Biosergen AB | 26.8 Million SEK | 79.414% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 87.507% |
| Alzinova AB (publ) | 36.39 Million SEK | 84.836% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 98.095% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 95.204% |
| Pila Pharma AB (publ) | 7.85 Million SEK | 29.75% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 95.024% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 62.456% |